Note: for 20 business days following May 18, 2023, it traded under the ticker symbol "EVFMD." On June 20, 2023, the ticker symbol reverted to "EVFM".
As of October 3, 2022, Evofem's common stock is traded on the OTCQB Venture Market. Quotes and related Company information are available at www.otcmarkets.com.
You must contact a registered broker to invest in Evofem (OTCQB: EVFM) common stock.
Effective May 18, 2023, Evofem's CUSIP is 30048L302.
Evofem became a public company through a reverse merger with Neothetics, Inc., which closed January 17, 2018.
Evofem, Inc. was incorporated in 2009. However, Evofem, Inc.'s ultimate parent company Evofem Biosciences, Inc. was incorporated in 2015
Evofem headquarters are in San Diego, CA.
As of August 16, 2023, there were approximately 4,060,209 shares of Evofem common stock and 1,800 shares of Series E-1 Convertible Preferred stock issued and outstanding. Please refer to the SEC filings webpage of the Investor section of our website for subsequent updates.
Pacific Stock Transfer
6725 Via Austi Pkwy Suite 300
Las Vegas, NV 89119
Pacific Stock Transfer’s business hours are 8:00 a.m. to 4:30 p.m. PST, Monday through Friday. Connect with them:
- Toll Free: 800-785-7782
- Phone: 702-361-3033
- Fax: 702-433-1979
- Email: email@example.com
Please contact firstname.lastname@example.org for instructions on how to exercise warrants before wiring funds to the Company.
May 2018 warrants (only) may be exercised directly through Philadelphia Stock Transfer by submitting a Deposit/Withdrawal by Custodian (DWAC) withdrawal on the warrants and a DWAC deposit on the common once exercise funds were confirmed and received. For more information, please contact Bob Winterle at Philadelphia Stock Transfer: email@example.com / 484.416.3124.
Please refer to the SEC filings webpage of the Investor section of our website.
Procopio, Cory, Hargreaves & Savitch LLP
Evofem Biosciences commercializes innovative products to address unmet needs in women's sexual and reproductive health.
Plans for reporting of Evofem's quarterly and annual financial results will be announced in advance; please check the Events and Presesntations section within the Investor section of our website for details, or sign up for news alerts to be notified by email.
The dates for stockholder meetings are determined by the Board of Directors and will be disclosed in our proxy filings with the SEC, which are available through the SEC Filings tab of the Investors section of our website (click here).
Evofem is on a calendar year that ends December 31.
Access information for quarterly and annual financial results calls and/or webcasts will be disclosed in a press release and included in the Events and Presentations section of our Investor Relations website.
Please contact Amy Raskopf, Senior Vice President of Investor Relations, at firstname.lastname@example.org or by phone at 917.673.5775.
You can sign up for e-mail alerts notifying you of new press releases, SEC filings or corporate actions and events on the “Investor Contacts and Alerts” page of the Investor section of our website.